Effectiveness and Quality-of-life Improvement with Fluticasone Furoate/Vilanterol in Asthma Patients: An Observational Study

Background and aim: Asthma represents a diverse set of pulmonary symptoms encompassing wheezing, dyspnea, chest congestion, and cough that evolve in severity and expiratory airflow resistance over time. Fluticasone furoate/vilanterol (FF/Vi) is used for asthma treatment globally. Currently, studies evaluating the efficacy of FF/Vi combination in asthmatic patients from India are scarce. This study aimed to evaluate the effectiveness of (FF/Vi) (100/25 µg) in asthma patients by measuring health-related quality of life (HRQoL) through the St George Respiratory Questionnaire (SGRQ) and spirometry.